Skip to main navigation Skip to search Skip to main content

Oral acute toxicity study and in vivo antimalarial activity of Strychnos lucida R. Br. tablet

  • Uswatun Khasanah*
  • , Queen Intan Nurrahmah
  • , Thia Amalia
  • , Zada Nabila Putri
  • , mufidah Imrokatul mufidah
  • , Roisatun Napik
  • , Diana Lyrawati
  • , Bachtiar Rifai Pratita Ihsan
  • , Maya Eka Febrianti
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Ethnopharmacological relevance: Malaria eradication has been a major goal of the Indonesian government since 2020. Medicinal plants, such as Strychnos lucida R. Br., are empirically used to treat malaria through traditional preparation methods. However, the safety and efficacy of these plants have not yet been confirmed. Therefore, further investigations are necessary to confirm the safety and efficacy of S. lucida as an antimalarial agent. Aims of the study: To quantify the concentration of brucine in the S. lucida extract, determine the acute oral toxicity of the standardized extract, and evaluate the in vivo antimalarial potency of S. lucida tablet (SLT). Materials and methods: Acute oral toxicity of S.lucida extract was determined using the Organization for Economic Co-operation and Development 420 procedure, and the analytical method for brucine quantification was validated using high-performance liquid chromatography. In addition, antimalarial activity was determined using the Peter's four-day suppressive method. Results: Acute toxicity analysis revealed S. lucida as a low-toxicity compound with a cut-off median lethal dose of 2000–5000 mg/kg body weight [BW], which was supported by the hematological and biochemical profiles of the kidneys, liver, and pancreas (p > 0.05). Extract standardization revealed that S. lucida contained 3.91 ± 0.074% w/w brucine, adhering to the limit specified in the Indonesian Herbal Pharmacopeia. Antimalarial test revealed that SLT inhibited the growth of Plasmodium berghei by 27.74–45.27%. Moreover, SLT improved the hemoglobin and hematocrit levels. White blood cell and lymphocyte counts were lower in the SLT-treated group than in the K (+) group (p < 0.05). Conclusion: Histopathological and biochemical evaluations revealed that S. lucida extract was safe at a dose of 2000 mg/kg BW with low toxicity. SLT inhibited Plasmodium growth and improved the hemoglobin, hematocrit, and red blood cell profiles. Additionally, SLT reduced the lymphocyte and WBC counts and increased the monocyte and thrombocyte counts as part of the immune system response against Plasmodium infection.

Original languageEnglish
Article number118200
JournalJournal of Ethnopharmacology
Volume330
DOIs
Publication statusPublished - 10 Aug 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Antimalarial
  • Brucine
  • Hematology
  • Oral acute toxicity
  • Strychnos lucida

Fingerprint

Dive into the research topics of 'Oral acute toxicity study and in vivo antimalarial activity of Strychnos lucida R. Br. tablet'. Together they form a unique fingerprint.

Cite this